Bacteriophage genes could lead to development of new antibiotics
New research has shown that 'hidden' lysis genes in bacteriophages could be used in the development of a new class of antibiotics.
List view / Grid view
New research has shown that 'hidden' lysis genes in bacteriophages could be used in the development of a new class of antibiotics.
In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.
Using a mouse model, researchers found that cancer progression led to fewer skeletal muscle ribosomes, likely explaining muscle wasting.
Researchers have found that SARS-CoV-2 evades immune responses by deleting parts of its genetic sequence that encode for the Spike protein.
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
A new protein can trick SARS-CoV-2 and bind to the Spike protein rather than cell membranes in a kidney organoid.
Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
Researchers have found that colorectal cancer-associated fibroblasts can be altered using a gremlin 1-neutralising antibody or by overexpressing meflin.
The discovery of early plasma biomarkers for Alzheimer's disease could transform outcomes by enabling patients to begin treatment early.
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
Researchers have identified a new compound that improved responses to insulin and treated diabetes in obese mouse models.
A team has developed a new way to discover peptide therapeutics that inhibit HDAC enzymes and are effective against cancer.
CAR T cells modified to recognise CEACAM7 were able to eliminate pancreatic ductal adenocarcinoma cells in a late-stage model without toxic effects on healthy tissue.